<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654782</url>
  </required_header>
  <id_info>
    <org_study_id>15-000858</org_study_id>
    <nct_id>NCT02654782</nct_id>
  </id_info>
  <brief_title>Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients</brief_title>
  <official_title>Lactated Ringer's Versus 5% Human Albumin: A Double-Blinded, Randomized, Prospective Study in Cardiac Surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William C. Oliver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show which of two different types of fluid is best for&#xD;
      cardiac surgical patients. During and after the subject's heart surgery, the subject will be&#xD;
      given either Lactated Ringer's or 5% human albumin to replace lost blood and body fluids and&#xD;
      to regulate blood pressure.&#xD;
&#xD;
      Albumin (human) 5% is a sterile, liquid preparation of albumin derived from large pools of&#xD;
      human plasma. All units of human plasma used in the manufacture of Albumin (human) 5% are&#xD;
      provided by FDA approved blood establishments only.&#xD;
&#xD;
      Lactated Ringer's is a sterile, nonpyrogenic solution containing isotonic concentrations of&#xD;
      electrolytes in water for injection. It is FDA approved for administration by intravenous&#xD;
      infusion for parental replacement of extracellular losses of fluid and electrolytes.&#xD;
&#xD;
      The hypothesis of this study is that the individual total fluid volume and alveolar-arterial&#xD;
      gradient will be less with 5% human albumin compared to Lactated Ringer's in the&#xD;
      perioperative cardiac surgical patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following Institutional Review Board (IRB) approval and written informed patient consent, 40&#xD;
      elective, cardiac surgical patients will be randomized to two different fluid therapy&#xD;
      regimens, 5% human albumin only or Lactated Ringer's only, beginning in the intraoperative&#xD;
      period and up to 6 hours in the intensive care unit. Providers and patients will be blinded&#xD;
      to the fluid administered in the operating room and intensive care unit. The primary outcome&#xD;
      measure will be the total volume of 5% human albumin or Lactated Ringer's given during the&#xD;
      study period to maintain specified hemodynamic guidelines. Hemodynamic instability will be&#xD;
      defined according to each patient's stipulated baseline parameters. Fluid will be&#xD;
      administered at the request of providers in the operating room and intensive care unit in&#xD;
      compliance with a perioperative fluid algorithm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Student performing study left Mayo Clinic, no funds to continue study.&#xD;
  </why_stopped>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">October 9, 2017</completion_date>
  <primary_completion_date type="Actual">October 9, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Fluid Administered Indexed to Weight</measure>
    <time_frame>Start of surgery up to 6 hours into the intensive care unit (ICU)</time_frame>
    <description>Adequate fluid volume plays a major part in maintaining the necessary hemodynamics to prevent organ damage during cardiac surgery. This will be measured by the total volume of fluid administered to the subject from the start of surgery up to 6 hours in the intensive care unit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alveolar-arterial Gradient</measure>
    <time_frame>Calculated throughout the study up to 6 hours in the ICU</time_frame>
    <description>Alveolar-arterial gradient will be calculated from arterial blood gases on each patient. This value will be used to compare shunt in each arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hemodynamic Stability</condition>
  <arm_group>
    <arm_group_label>Lactated Ringer's</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5% Human Albumin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactated Ringer's</intervention_name>
    <description>Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.</description>
    <arm_group_label>Lactated Ringer's</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% Human Albumin</intervention_name>
    <description>Colloid given for hemodynamic resuscitation based off of individual patient needs.</description>
    <arm_group_label>5% Human Albumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-pregnant female patients&#xD;
&#xD;
          -  Patients undergoing elective cardiac surgery&#xD;
&#xD;
          -  Aspirin, heparin, or warfarin preoperatively accepted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous sternotomy&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Combined procedures (vascular or thoracic operations)&#xD;
&#xD;
          -  Congenital heart repair&#xD;
&#xD;
          -  Hypothermic cardiopulmonary bypass (CPB) &lt; 28 degrees C&#xD;
&#xD;
          -  Serum creatinine greater than or equal to 1.5 mg/dL&#xD;
&#xD;
          -  Dialysis dependent renal failure&#xD;
&#xD;
          -  Neurologic injury or event within 30 days (including transient ischemic attack)&#xD;
&#xD;
          -  Cerebrovascular accident with significant residual neurologic deficit&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease with Forced Expiratory Volume in 1 Second&#xD;
             (FEV1) &lt; 45% of predicted value&#xD;
&#xD;
          -  Home oxygen use&#xD;
&#xD;
          -  Previous difficult intubation&#xD;
&#xD;
          -  Acute normovolemic blood conservation techniques&#xD;
&#xD;
          -  Liver disease with serum aspartate aminotransferase (AST) &gt; 31 U/L&#xD;
&#xD;
          -  Circulatory arrest&#xD;
&#xD;
          -  Thrombolysis&#xD;
&#xD;
          -  Pre-existing clotting disorder&#xD;
&#xD;
          -  Platelet receptor glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist medication received&#xD;
             within 48 hours&#xD;
&#xD;
          -  Steroids&#xD;
&#xD;
          -  Ejection Fraction &lt; 40%&#xD;
&#xD;
          -  Intra-aortic balloon pumps&#xD;
&#xD;
          -  Ongoing congestive heart failure&#xD;
&#xD;
          -  Ventricular assist devices&#xD;
&#xD;
          -  Total hearts&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Adults lacking capacity to consent&#xD;
&#xD;
          -  Any patients initially enrolled in the study that end up with an intra-aortic balloon&#xD;
             pump, left ventricular assist device, or on extracorporeal membrane oxygenation will&#xD;
             be eliminated from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Oliver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <results_first_submitted>November 16, 2018</results_first_submitted>
  <results_first_submitted_qc>March 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 16, 2019</results_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>William C. Oliver</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Lactated Ringer's</keyword>
  <keyword>Human Albumin</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT02654782/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lactated Ringer's</title>
          <description>Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
Lactated Ringer's: Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.</description>
        </group>
        <group group_id="P2">
          <title>5% Human Albumin</title>
          <description>Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
5% Human Albumin: Colloid given for hemodynamic resuscitation based off of individual patient needs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lactated Ringer's</title>
          <description>Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
Lactated Ringer's: Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.</description>
        </group>
        <group group_id="B2">
          <title>5% Human Albumin</title>
          <description>Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
5% Human Albumin: Colloid given for hemodynamic resuscitation based off of individual patient needs.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian, Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Fluid Administered Indexed to Weight</title>
        <description>Adequate fluid volume plays a major part in maintaining the necessary hemodynamics to prevent organ damage during cardiac surgery. This will be measured by the total volume of fluid administered to the subject from the start of surgery up to 6 hours in the intensive care unit.</description>
        <time_frame>Start of surgery up to 6 hours into the intensive care unit (ICU)</time_frame>
        <population>The study was terminated early. This was a student project and the student performing the study left Mayo Clinic and there were no funds to continue study. Targeted enrollment of 40 subjects was not met and data was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Lactated Ringer's</title>
            <description>Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
Lactated Ringer's: Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.</description>
          </group>
          <group group_id="O2">
            <title>5% Human Albumin</title>
            <description>Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
5% Human Albumin: Colloid given for hemodynamic resuscitation based off of individual patient needs.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fluid Administered Indexed to Weight</title>
          <description>Adequate fluid volume plays a major part in maintaining the necessary hemodynamics to prevent organ damage during cardiac surgery. This will be measured by the total volume of fluid administered to the subject from the start of surgery up to 6 hours in the intensive care unit.</description>
          <population>The study was terminated early. This was a student project and the student performing the study left Mayo Clinic and there were no funds to continue study. Targeted enrollment of 40 subjects was not met and data was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alveolar-arterial Gradient</title>
        <description>Alveolar-arterial gradient will be calculated from arterial blood gases on each patient. This value will be used to compare shunt in each arm.</description>
        <time_frame>Calculated throughout the study up to 6 hours in the ICU</time_frame>
        <population>The study was terminated early. This was a student project and the student performing the study left Mayo Clinic and there were no funds to continue study. Targeted enrollment of 40 subjects was not met and data was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Lactated Ringer's</title>
            <description>Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
Lactated Ringer's: Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.</description>
          </group>
          <group group_id="O2">
            <title>5% Human Albumin</title>
            <description>Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
5% Human Albumin: Colloid given for hemodynamic resuscitation based off of individual patient needs.</description>
          </group>
        </group_list>
        <measure>
          <title>Alveolar-arterial Gradient</title>
          <description>Alveolar-arterial gradient will be calculated from arterial blood gases on each patient. This value will be used to compare shunt in each arm.</description>
          <population>The study was terminated early. This was a student project and the student performing the study left Mayo Clinic and there were no funds to continue study. Targeted enrollment of 40 subjects was not met and data was not analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 6 hours after surgery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lactated Ringer's</title>
          <description>Subjects randomized to Lactated Ringer's for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
Lactated Ringer's: Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.</description>
        </group>
        <group group_id="E2">
          <title>5% Human Albumin</title>
          <description>Subjects randomized to 5% human albumin for hemodynamic resuscitation. Volume will be decided based off of individual patient needs.&#xD;
5% Human Albumin: Colloid given for hemodynamic resuscitation based off of individual patient needs.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early. This was a student project and the student performing the study left Mayo Clinic and there were no funds to continue study. Targeted enrollment of 40 subjects was not met and data was not analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. William C. Oliver, Jr.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-4240</phone>
      <email>oliver.william@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

